Literature DB >> 12204956

In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K.

Neil M Ampel1, Larissa A Kramer, Lijin Li, Deborah S Carroll, Kathleen M Kerekes, Suzanne M Johnson, Demosthenes Pappagianis.   

Abstract

Measurement of cellular immunity in human coccidioidomycosis has important diagnostic and prognostic implications. The coccidioidin skin test has been the standard for the measurement of this, but it is not available in the United States. We examined the utility of measuring surface expression of CD69 on T lymphocytes in whole blood incubated with the coccidioidal antigen preparation T27K as an alternative to the skin test. Seventy donors with active coccidioidomycosis were studied. The mean fluorescent intensity (MFI) of CD69 expression on CD3 lymphocytes in response to T27K was 28.61 +/- 1.77, significantly greater than the control response of 11.45 +/- 0.78 (P < 0.001). The MFI CD69 response to T27K above that for the control (MFI CD69 above control) was 6.35 +/- 2.18 for seven subjects with disseminated coccidioidomycosis who were studied within 5 months of diagnosis. This was significantly below the value of 20.17 +/- 3.17 for 18 subjects with pulmonary coccidioidomycosis studied within 5 months of diagnosis and the value of 19.58 +/- 2.91 for 27 subjects with disseminated coccidioidomycosis studied after 5 months of diagnosis (for both, P < 0.05). There was an inverse correlation between coccidioidal clinical score and MFI CD69 above control for all 34 subjects with disseminated coccidioidomycosis (r = 0.362; P = 0.036) but not for the 36 subjects with pulmonary disease (r < 0.001; P = 0.993). Among 30 subjects for whom data were available, there was a highly significant association between the MFI CD69 above control and the supernatant concentrations of gamma interferon, interleukin-2 (IL-2), and tumor necrosis factor alpha (for all, P < 0.001), but not for IL-4, IL-5, or IL-10. These data indicate that in vitro assessment of CD69 expression on T lymphocytes by using T27K may be a useful measure of cellular immune response among subjects with active coccidioidomycosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12204956      PMCID: PMC120057          DOI: 10.1128/cdli.9.5.1039-1043.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  Coccidioidin skin testing in Kern County, California: decrease in infection rate over 58 years.

Authors:  T R Larwood
Journal:  Clin Infect Dis       Date:  2000-03       Impact factor: 9.079

2.  Cellular immune response in coccidioidomycosis.

Authors:  A Catanzaro; L E Spitler; K M Moser
Journal:  Cell Immunol       Date:  1975-02       Impact factor: 4.868

3.  Spectrum of in vivo and in vitro cell-mediated immune responses in coccidioidomycosis.

Authors:  R A Cox; J R Vivas
Journal:  Cell Immunol       Date:  1977-06-01       Impact factor: 4.868

4.  Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases.

Authors:  C E SMITH; R R BEARD
Journal:  Am J Public Health Nations Health       Date:  1946-12

5.  In vitro lymphocyte responses of coccidioidin skin test-positive and -negative persons to coccidioidin, spherulin, and a coccidioides cell wall antigen.

Authors:  R A Cox; E Brummer; G Lecara
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

6.  Cell-mediated immune response to tuberculosis antigens: comparison of skin testing and measurement of in vitro gamma interferon production in whole-blood culture.

Authors:  R K Katial; J Hershey; T Purohit-Seth; J T Belisle; P J Brennan; J S Spencer; R J Engler
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

7.  Assessment of the human cellular immune response to T27K, a coccidioidal antigen preparation, by flow cytometry of whole blood.

Authors:  N M Ampel; L A Kramer; K M Kerekes; S M Johnson; D Pappagianis
Journal:  Med Mycol       Date:  2001-08       Impact factor: 4.076

8.  Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection.

Authors:  G H Mazurek; P A LoBue; C L Daley; J Bernardo; A A Lardizabal; W R Bishai; M F Iademarco; J S Rothel
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

9.  Restoration of cellular immunity against tuberculosis in patients coinfected with HIV-1 and tuberculosis with effective antiretroviral therapy: assessment by determination of CD69 expression on T cells after tuberculin stimulation.

Authors:  S M Hsieh; C C Hung; S C Pan; J T Wang; H C Tsai; M Y Chen; S C Chang
Journal:  J Acquir Immune Defic Syndr       Date:  2000-11-01       Impact factor: 3.731

10.  Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group.

Authors:  J N Galgiani; A Catanzaro; G A Cloud; R H Johnson; P L Williams; L F Mirels; F Nassar; J E Lutz; D A Stevens; P K Sharkey; V R Singh; R A Larsen; K L Delgado; C Flanigan; M G Rinaldi
Journal:  Ann Intern Med       Date:  2000-11-07       Impact factor: 25.391

View more
  17 in total

Review 1.  Measurement of cellular immunity in human coccidioidomycosis.

Authors:  Neil M Ampel
Journal:  Mycopathologia       Date:  2003       Impact factor: 2.574

2.  An archived lot of coccidioidin induces specific coccidioidal delayed-type hypersensitivity and correlates with in vitro assays of coccidioidal cellular immune response.

Authors:  Neil M Ampel; Richard F Hector; Christina P Lindan; George W Rutherford
Journal:  Mycopathologia       Date:  2006-02       Impact factor: 2.574

3.  Cytokine Profiles from Antigen-Stimulated Whole-Blood Samples among Patients with Pulmonary or Nonmeningeal Disseminated Coccidioidomycosis.

Authors:  Neil M Ampel; Lance A Nesbit; Chinh T Nguyen; Suzette Chavez; Kenneth S Knox; Suzanne M Johnson; Demosthenes Pappagianis
Journal:  Clin Vaccine Immunol       Date:  2015-06-03

4.  Preliminary evaluation of whole-blood gamma interferon release for clinical assessment of cellular immunity in patients with active coccidioidomycosis.

Authors:  Neil M Ampel; Daniel K Nelson; Suzette Chavez; Kathryn A Naus; Amanda B Herman; Lijin Li; Keira A Simmons; Demosthenes Pappagianis
Journal:  Clin Diagn Lab Immunol       Date:  2005-06

5.  Vaccine immunity to coccidioidomycosis occurs by early activation of three signal pathways of T helper cell response (Th1, Th2, and Th17).

Authors:  Chiung-Yu Hung; Angel Gonzalez; Marcel Wüthrich; Bruce S Klein; Garry T Cole
Journal:  Infect Immun       Date:  2011-08-22       Impact factor: 3.441

Review 6.  Coccidioidomycosis: host response and vaccine development.

Authors:  Rebecca A Cox; D Mitchell Magee
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Preclinical identification of vaccine induced protective correlates in human leukocyte antigen expressing transgenic mice infected with Coccidioides posadasii.

Authors:  Brady J Hurtgen; Natalia Castro-Lopez; Maria Del Pilar Jiménez-Alzate; Garry T Cole; Chiung-Yu Hung
Journal:  Vaccine       Date:  2016-09-09       Impact factor: 3.641

8.  Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts.

Authors:  Janis E Blair; Brandon Coakley; Ana C Santelli; Joseph G Hentz; Nancy L Wengenack
Journal:  Mycopathologia       Date:  2006-11       Impact factor: 2.574

Review 9.  Valley fever: danger lurking in a dust cloud.

Authors:  Larry Johnson; Erin M Gaab; Javier Sanchez; Phuong Q Bui; Clarissa J Nobile; Katrina K Hoyer; Michael W Peterson; David M Ojcius
Journal:  Microbes Infect       Date:  2014-07-16       Impact factor: 2.700

10.  Protein expression profiling of Coccidioides posadasii by two-dimensional differential in-gel electrophoresis and evaluation of a newly recognized peroxisomal matrix protein as a recombinant vaccine candidate.

Authors:  Kris I Orsborn; Lisa F Shubitz; Tao Peng; Ellen M Kellner; Marc J Orbach; Paul A Haynes; John N Galgiani
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.